Skip to main content
. 2013 Sep;5(Suppl 4):S397–S406. doi: 10.3978/j.issn.2072-1439.2013.08.08

Table 1. High lightened studies of platinum based chemotherapy as first line treatment of malignant pleural mesothelioma, (EAP, International Expanded Access Program).

First name, year, ref Phase/study n Chemotherapy regimen Response rates (RR) Median progression-free survival (PFS) months Median overall survival (OS) months Outcome
Vogelzang, 2003 (45) III 226 Cisplatin + pemetrexed 41.3% 5.7 12.1 Satisfactory, superior to cisplatin
Van Meerbeeck, 2005 (45) III 126 Cisplatin + raltitrexed 23.6% 11.4 Satisfactory, superior to cisplatin alone
Ceresoli et al. 2006 (46) II 102 Carboplatin plus pemetrexed 18.6% 6.5 12.7 Satisfactory, combination active and well tolerated
Obasaju, 2007 (47) EAP 728 Cisplatin + pemetrexed 21% 10.8 Satisfactory, MPM patients experience a response or stable disease
Santoro, 2008 (48) EAP 861 Cisplatin + pemetrexed 22% Satisfactory, 1-year survival rates
Hillerdal, 2008 (49) II 173 Carboplatin + gemcitabine + liposomal doxorubicin 33% 13 Satisfactory, high number of responses and long survival, and a low toxicity